Pediatr Transplant. 2008 Jan 8 [Epub ahead of print]
Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation
Megged O, Shalit I, Yaniv I, Stein J, Fisher S, Levy I.
Infectious Diseases Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
We describe a case of breakthrough cerebral toxoplasmosis during atovaquone therapy in a child who was intolerant of conventional prophylactic regimens after hematopoietic stem cell transplantation. The available data on the efficacy of atovaquone prophylaxis in Toxoplasma sero-positive stem cell transplant recipients remain limited, and other strategies, such as preemptive strategy using toxoplasma PCR or TMP-SMX desensitization should be considered in this setting.
PMID: 18194354 [PubMed - as supplied by publisher]